AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19014837 — intervention group
Group type: COMPARATOR
Intervention: LC15-0444
Number of subjects: 60
Study 16863968 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis Z9000 IOL
Number of subjects: 30
Study 16863968 — intervention group
Group type: COMPARATOR
Intervention: AR40e IOL
Number of subjects: 30
Study 16863968 — intervention group
Group type: COMPARATOR
Intervention: Stabibag IOL
Number of subjects: 30
Study 12752543 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-thymol varnish applications every 3 months for 24 months
Number of subjects: 0
Study 12752543 — intervention group
Group type: COMPARATOR
Intervention: Control group (no varnish applications)
Number of subjects: 0
Study 10691216 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg morphine
Number of subjects: 9
Study 10691216 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 9
Study 9226432 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% zinc chloride
Number of subjects: 11
Study 9226432 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine
Number of subjects: 11
Study 9226432 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing 2 mg zinc acetate
Number of subjects: 11
Study 9226432 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing 0.5 mg zinc acetate
Number of subjects: 11
Study 9226432 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing 0 mg zinc acetate
Number of subjects: 11
Study 9226432 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinses containing zinc
Number of subjects: 11
Study 9226432 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 11
Study 8443808 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 alone
Number of subjects: 38
Study 8443808 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus IFN-alpha
Number of subjects: 38
Study 8443808 — intervention group
Group type: COMPARATOR
Intervention: IL-2 and IFN-alpha
Number of subjects: 38
Study 3014770 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliomyelitis vaccine (IPV)
Number of subjects: 160
Study 3014770 — intervention group
Group type: COMPARATOR
Intervention: Oral poliomyelitis vaccine (OPV)
Number of subjects: 160
Study 29380915 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chocolate milk
Number of subjects: 136
Study 29380915 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk samples collected in West region supermarkets
Number of subjects: 136
Study 29380915 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat content
Number of subjects: 136
Study 29380915 — intervention group
Group type: COMPARATOR
Intervention: Macronutrient content
Number of subjects: 136
Study 27729579 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10-mg and folic acid 0.8-mg tablet
Number of subjects: 20702
Study 27729579 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10-mg tablet alone
Number of subjects: 20702
Study 25458657 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist case management
Number of subjects: 275
Study 25458657 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case management
Number of subjects: 275
Study 22696542 — intervention group
Group type: EXPERIMENTAL
Intervention: Small object lifting (wood-filled and brass-filled)
Number of subjects: 0
Study 22696542 — intervention group
Group type: EXPERIMENTAL
Intervention: First lift of the large block (after lifting small objects)
Number of subjects: 0
Study 19621225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2b (6 microg/kg/week for 8 weeks, then 3 microg/kg/week for up to 5 years)
Number of subjects: 48
Study 19621225 — intervention group
Group type: COMPARATOR
Intervention: Observation only (control group)
Number of subjects: 48
Study 18773156 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d) plus Ezetimibe (10 mg/d)
Number of subjects: 305
Study 18773156 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin (80 mg/d)
Number of subjects: 305
Study 16182346 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dosage of 20 ml PCC based on target-INR of 2.1 or 1.5, initial-INR, and patient's body weight (group B)
Number of subjects: 93
Study 16182346 — intervention group
Group type: COMPARATOR
Intervention: Standard dosage of 20 ml PCC equivalent to about 500 IU factor IX (group A)
Number of subjects: 93
Study 12817355 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint consultation with cardiologists
Number of subjects: 306
Study 12817355 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 306
Study 10984002 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (mean dose 0.70 mg/d, mean duration 24.4 weeks)
Number of subjects: 32
Study 10984002 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 32
Study 8791959 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g mesalazine in 30 mL (group I, n = 10)
Number of subjects: 31
Study 8791959 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g mesalazine in 60 mL (group II, n = 12)
Number of subjects: 31
Study 8791959 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g mesalazine in 100 mL (group III, n = 9)
Number of subjects: 31
Study 1612319 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (3 mg/kg) administered IV for 15 minutes
Number of subjects: 17
Study 1612319 — intervention group
Group type: COMPARATOR
Intervention: Saline administered IV for 15 minutes
Number of subjects: 17
Study 6368353 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 15
Study 6368353 — intervention group
Group type: COMPARATOR
Intervention: Intensified conventional insulin treatment (CIT)
Number of subjects: 15
Study 6368353 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CSII and CIT)
Number of subjects: 15
Study 29747810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense care of oral hygiene (powered toothbrush and 1% chlorhexidine oral gel)
Number of subjects: 0
Study 29747810 — intervention group
Group type: COMPARATOR
Intervention: Standard care of oral hygiene (manual toothbrush and toothpaste)
Number of subjects: 0
Study 26963601 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Behavioral Couples Therapy (G‐BCT) plus 12-step-oriented Individually Based Therapy (IBT)
Number of subjects: 101
Study 26963601 — intervention group
Group type: COMPARATOR
Intervention: Standard Behavioral Couples Therapy (S‐BCT) plus Individually Based Therapy (IBT)
Number of subjects: 101
Study 25332472 — intervention group
Group type: EXPERIMENTAL
Intervention: Water and education provision (WEP) group
Number of subjects: 240
Study 25332472 — intervention group
Group type: COMPARATOR
Intervention: Education provision (EP) group
Number of subjects: 240
Study 22742672 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant Healing Intention (DHI) - Blinded group
Number of subjects: 72
Study 22742672 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant Healing Intention (DHI) - Expectancy group (knowing they were receiving DHI)
Number of subjects: 72
Study 22742672 — intervention group
Group type: COMPARATOR
Intervention: Control group (blinded and not receiving DHI)
Number of subjects: 72
Study 22742672 — intervention group
Group type: EXPERIMENTAL
Intervention: DHI under blinded conditions
Number of subjects: 72
Study 22742672 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief in DHI efficacy
Number of subjects: 72
Study 22742672 — intervention group
Group type: EXPERIMENTAL
Intervention: Healers' perceptions of subjective 'contact' with participants
Number of subjects: 72
Study 20456336 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg/week
Number of subjects: 40
Study 20456336 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 40
Study 18622068 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive tramadol (iv injection of tramadol 100 mg 15 min before operation)
Number of subjects: 317
Study 18622068 — intervention group
Group type: COMPARATOR
Intervention: Preventive tramadol (same dose of tramadol 100 mg 15 min before the end of the operation)
Number of subjects: 317
Study 15685350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejaculated spermatozoa (Group 1)
Number of subjects: 46
Study 15685350 — intervention group
Group type: EXPERIMENTAL
Intervention: Testicular spermatozoa (Group 2)
Number of subjects: 46
Study 15685350 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 11889427 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 microg)
Number of subjects: 53
Study 11889427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 10213466 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-beta1 in patients with microbiologically positive pneumonia
Number of subjects: 0
Study 10213466 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-beta2 in patients with pneumonia
Number of subjects: 0
Study 10213466 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotrienes C4, D4, and E4 in patients with pneumonia
Number of subjects: 0
Study 10213466 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene B4 in patients with pneumonia
Number of subjects: 0
Study 10213466 — intervention group
Group type: EXPERIMENTAL
Intervention: PMN elastase in patients with pneumonia
Number of subjects: 0
Study 10213466 — intervention group
Group type: EXPERIMENTAL
Intervention: Neopterin in patients with pneumonia
Number of subjects: 0
Study 10213466 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of TGF-beta1 with IL-8 levels
Number of subjects: 0
Study 10213466 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of TGF-beta1 with percentage of granulocytes
Number of subjects: 0
Study 7789488 — intervention group
Group type: EXPERIMENTAL
Intervention: Protriptyline 10 mg daily
Number of subjects: 26
Study 7789488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 2141757 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g n-3 fatty acids
Number of subjects: 45
Study 2141757 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g n-3 fatty acids
Number of subjects: 45
Study 2141757 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g n-3 fatty acids
Number of subjects: 45
Study 2141757 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 45
Study 465277 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT) 12.5 mg and 25 mg
Number of subjects: 0
Study 465277 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 0
Study 465277 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HCT and metoprolol
Number of subjects: 0
Study 31752859 — intervention group
Group type: COMPARATOR
Intervention: Nursing hours per patient day (NHPPD)
Number of subjects: 68
Study 31752859 — intervention group
Group type: COMPARATOR
Intervention: Proportion of nurse Bachelor hours
Number of subjects: 68
Study 27443836 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth
Number of subjects: 4262
Study 27443836 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 4262
Study 25872782 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic guided bedside placement of nasoenteral feeding tubes
Number of subjects: 154
Study 25872782 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic placement of nasoenteral feeding tubes
Number of subjects: 154
Study 23664327 — intervention group
Group type: EXPERIMENTAL
Intervention: IMN irradiation
Number of subjects: 1334
Study 23664327 — intervention group
Group type: COMPARATOR
Intervention: No IMN irradiation (control)
Number of subjects: 1334
Study 21899891 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaltenborn manual therapy
Number of subjects: 29
Study 21899891 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 29
Study 19132974 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glucocorticoids (GC)
Number of subjects: 39
Study 19132974 — intervention group
Group type: COMPARATOR
Intervention: Non-GC treated NP
Number of subjects: 39
Study 16766330 — intervention group
Group type: EXPERIMENTAL
Intervention: Exomega milk applied twice a day for 2 months
Number of subjects: 76
Study 16766330 — intervention group
Group type: COMPARATOR
Intervention: Cleansing bar only (non-treated group)
Number of subjects: 76
Study 14722203 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus MTX (3 mg/kg or 10 mg/kg every 4 or 8 weeks)
Number of subjects: 428
Study 14722203 — intervention group
Group type: COMPARATOR
Intervention: MTX-only (placebo with MTX)
Number of subjects: 428
Study 11491130 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention with an interactive graphic card and verbal reinforcement
Number of subjects: 315
Study 11491130 — intervention group
Group type: COMPARATOR
Intervention: Routine information (Control)
Number of subjects: 315
Study 11491130 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 315
Study 9756005 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial daily administration of 6 million units of natural interferon-alpha subcutaneously for 2 weeks, then thrice a week for 22 weeks (Group A)
Number of subjects: 105
Study 9756005 — intervention group
Group type: COMPARATOR
Intervention: Thrice a week administration of 6 million units of natural interferon-alpha for 26 weeks (Group B)
Number of subjects: 105
Study 9756005 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial daily administration of interferon (Group A)
Number of subjects: 105
Study 9756005 — intervention group
Group type: COMPARATOR
Intervention: Thrice a week administration of interferon (Group B)
Number of subjects: 105
Study 9756005 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial daily administration of interferon (Group A) in patients with genotype 1b
Number of subjects: 105
Study 9756005 — intervention group
Group type: COMPARATOR
Intervention: Thrice a week administration of interferon (Group B) in patients with genotype 1b
Number of subjects: 105
Study 8147101 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine
Number of subjects: 0
Study 8147101 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 3145297 — intervention group
Group type: EXPERIMENTAL
Intervention: GRF 0.05 micrograms/Kg
Number of subjects: 6
Study 3145297 — intervention group
Group type: EXPERIMENTAL
Intervention: GRF 0.05 micrograms/Kg + TRH 400 micrograms
Number of subjects: 6
Study 3145297 — intervention group
Group type: EXPERIMENTAL
Intervention: GRF 0.1 micrograms/Kg
Number of subjects: 6
Study 3145297 — intervention group
Group type: EXPERIMENTAL
Intervention: GRF 1 microgram/Kg
Number of subjects: 6
Study 3145297 — intervention group
Group type: EXPERIMENTAL
Intervention: GRF 0.05 micrograms/Kg + TRH 20 micrograms
Number of subjects: 6
Study 3145297 — intervention group
Group type: EXPERIMENTAL
Intervention: GRF 1 microgram/Kg + TRH 400 micrograms
Number of subjects: 6
Study 3145297 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control treatment)
Number of subjects: 6
Study 30661697 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ) 200 ml/day for 6 weeks
Number of subjects: 60
Study 30661697 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 29055956 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher daily salt intake (2.0 g/day higher compared with normal weight individuals) after multivariable adjustment, 95% CI, 1.2‐2.8 g/day, P < 0.001
Number of subjects: 0
Study 29055956 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased activity in brain regions (orbitofrontal cortex, insula, parahippocampus)
Number of subjects: 0
Study 25315830 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (386.3 mg/day)
Number of subjects: 1098
Study 25315830 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (3.2 mg/day)
Number of subjects: 1098
Study 25315830 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 1098
Study 23351822 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 2331
Study 23351822 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2331
Study 21574968 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 16 mg/kg (Study A)
Number of subjects: 0
Study 21574968 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg (Study B)
Number of subjects: 0
Study 21574968 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline) (Study A)
Number of subjects: 0
Study 18956190 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryan Cervical Disc replacement (31 patients)
Number of subjects: 65
Study 18956190 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical fusion with iliac crest autograft and plate (34 patients)
Number of subjects: 65
Study 16965429 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl aminolaevulinate-based photodynamic therapy (MAL-PDT) for actinic keratosis (AK)
Number of subjects: 12
Study 16965429 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl aminolaevulinate-based photodynamic therapy (MAL-PDT) for nodular basal cell carcinoma (BCC)
Number of subjects: 12
Study 16965429 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl aminolaevulinate-based photodynamic therapy (MAL-PDT) for superficial basal cell carcinoma (BCC)
Number of subjects: 12
Study 16965429 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy for actinic keratosis (AK)
Number of subjects: 12
Study 16965429 — intervention group
Group type: COMPARATOR
Intervention: Excision surgery for basal cell carcinoma (BCC)
Number of subjects: 12
Study 15292315 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 48
Study 15292315 — intervention group
Group type: COMPARATOR
Intervention: No raloxifene (Control)
Number of subjects: 48
Study 11475456 — intervention group
Group type: EXPERIMENTAL
Intervention: High heeled shoes
Number of subjects: 10
Study 11475456 — intervention group
Group type: EXPERIMENTAL
Intervention: Leather shoes
Number of subjects: 10
Study 11475456 — intervention group
Group type: COMPARATOR
Intervention: Running shoes
Number of subjects: 10
Study 11475456 — intervention group
Group type: COMPARATOR
Intervention: Flat leather shoes
Number of subjects: 10
Study 9757419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rt-PA
Number of subjects: 615
Study 9757419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615
Study 7879632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (various intervention sequences)
Number of subjects: 21
Study 7879632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 21
Study 2903817 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg twice daily)
Number of subjects: 0
Study 2903817 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 0
Study 2903817 — intervention group
Group type: COMPARATOR
Intervention: Clemastine
Number of subjects: 0
Study 29998524 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-inhibitor (C1-INH) subcutaneous (SC) administration, 40 IU/kg twice weekly
Number of subjects: 124
Study 29998524 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-inhibitor (C1-INH) subcutaneous (SC) administration, 60 IU/kg twice weekly
Number of subjects: 124
Study 29998524 — intervention group
Group type: COMPARATOR
Intervention: C1-inhibitor (C1-INH) intravenous (IV) administration, 1000 IU
Number of subjects: 124
Study 26014092 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac patch applied twice a day for 7 days
Number of subjects: 164
Study 26014092 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch applied twice a day for 7 days
Number of subjects: 164
Study 26014092 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac patch
Number of subjects: 164
Study 26014092 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 164
Study 24596084 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy combined with steroid pulses
Number of subjects: 72
Study 24596084 — intervention group
Group type: COMPARATOR
Intervention: Steroid pulses alone
Number of subjects: 72
Study 23652861 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 200
Study 23652861 — intervention group
Group type: COMPARATOR
Intervention: Noncilostazol (Control)
Number of subjects: 200
Study 20101454 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual health seminars for HIV+ MSM
Number of subjects: 675
Study 20101454 — intervention group
Group type: COMPARATOR
Intervention: Contrast prevention video arm
Number of subjects: 675
Study 18215213 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/d
Number of subjects: 61
Study 18215213 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 300 mg/d
Number of subjects: 61
Study 18215213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 12365887 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen administered before surgery and regular doses after discharge for 72 hours
Number of subjects: 300
Study 12365887 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen administered at discharge
Number of subjects: 300
Study 12365887 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen doses after discharge
Number of subjects: 300
Study 12365887 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of the child
Number of subjects: 300
Study 12365887 — intervention group
Group type: EXPERIMENTAL
Intervention: Worst pain at rest
Number of subjects: 300
Study 12365887 — intervention group
Group type: EXPERIMENTAL
Intervention: Worst pain during swallowing
Number of subjects: 300
Study 12365887 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of separation from parents
Number of subjects: 300
Study 9656896 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 21
Study 9656896 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency transcutaneous electrical nerve stimulation (low-TENS)
Number of subjects: 21
Study 8135325 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.7 mmol (167 mg) magnesium aspartate
Number of subjects: 300
Study 8135325 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Na-aspartate)
Number of subjects: 300